Promising skin cancer trial pulled before it even started
NCT ID NCT02943642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a new drug called Resimmune against an oral medication (Zolinza) for people with a type of skin lymphoma called mycosis fungoides. The goal was to see if a single four-day treatment could completely clear skin lesions. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?
- Combination therapy aims to boost response in rare skin cancers
- Supercharged immune cells aim to stop lymphoma comeback
- Massive T-Cell lymphoma database aims to unlock new insights
- Can a body wash improve skin bacteria in lymphoma patients?